Shenzhen Chipscreen Biosciences Co (688321 SHG) stock market data APIs
¥22.0569
-0.11(-0.5%)
as of October 15, 2026
Try our APIs with
free plan!
Shenzhen Chipscreen Biosciences Co Financial Data Overview
Price chart is built with
Anychart
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the pharmaceutical industry in China. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for peripheral T-cell lymphoma, breast cancer, and diffuse large B-cell lymphoma indications; Chiglitazar, a PPAR full agonist for diabetes treatment; Siglitazone for metabolism treatment area; and Cioronib, a novel molecular, which selectively inhibits tumor-related protein kinase targets. It is also involved in the development of CS23546, a small molecule PD-L1 inhibitor, which relieves the immunosuppressive activity mediated by the PD-1/PD-L1 signaling pathway; CS231295, a brain-penetrating selective Aurora B inhibitor; and CS32582, a small-molecule allosteric inhibitor of tyrosine kinase 2. In addition, the company develops CS08399, a potential brain-penetrating PRMT5-MTA inhibitor for BIC; CS12088, a hepatitis B nucleocapsid assembly modulator; and CS12192, a highly selective JAK3 kinase inhibitor. Shenzhen Chipscreen Biosciences Co., Ltd. was founded in 2001 and is headquartered in Shenzhen, China.
Prev. Close
22.0569
Open
21.9468
High
22.463
Low
21.6392
52 wk Range
21.45-36.47
Market Cap
9 975 M
P/E Ratio
102.3636
Shares Outstanding
443 M
Revenue
1 047 M
EPS
0.4615
Dividends (Yield)
0.0026
Beta
0.658
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Shenzhen Chipscreen Biosciences Co (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Shenzhen Chipscreen Biosciences Co data using free add-ons & libraries
Get Shenzhen Chipscreen Biosciences Co Fundamental Data
Shenzhen Chipscreen Biosciences Co Fundamental data includes:
- Net Revenue: 1 047 M
- EBITDA: 208 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
Get Shenzhen Chipscreen Biosciences Co Earnings data
Corporate Events Calendar & News package for
$
19.99
/mo.
What’s included:
- Latest Release: 2023-08-11
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Shenzhen Chipscreen Biosciences Co News
New
Chipscreen NewWay: First Patient Dosed in Phase 1 Trial of the Bispecific Antibody NWY001, a Next-generation Tumor Immunotherapy in Patients with Advanced Solid Tumors
CHENGDU, China, Jan. 16, 2024 /PRNewswire/ -- Chengdu Chipscreen NewWay Biosciences Co., Ltd. (NewWay) announced that on January 5, 2024, the dosing of the first patient for a phase I clinical trial o...
Chipscreen's New Drug Candidate CS32582 Capsules Approved for Clinical Treatment of Psoriasis
SHENZHEN, China, Nov. 2, 2023 /PRNewswire/ -- On Oct. 31, 2023, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen" and with stock code 688321.SH) received the "Drug Cl...
Biocytogen’s Subsidiary Eucure Biopharma and Chipscreen Biosciences’ Holding Subsidiary Chipscreen NewWay Biosciences Enter into Greater China License Agreement for Bispecific Antibody YH008
BEIJING, February 27, 2023--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that its wholly owned subsidiary, Eucure (Beijing) Biopharma Co....
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinosta...
Get Shenzhen Chipscreen Biosciences Co fresh news feed via Financial News API
Corporate Events Calendar & News package for
$19.99/mo.
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
Best Offer
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.